A Randomised Phase II Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone in Intermediate and High Risk Clinically Localized Prostate Cancer
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- 3 year biochemical progression free survival (PSA)
研究概览
简要总结
This study investigates neoadjuvant TAK-700 orteronel for 6 months prior to prostatectomy. The three year biochemical free survival is the primary endpoint. There are a number of 2nd endpoints such as pathological complete response rate, the need for adjuvant radiation therapy, use of post operative radiotherapy an the rate of positive margins at surgery. Translational endpoints include measuring tumoural and plasma testosterone as well as other androgens.
Patients with untreated high risk and intermediate risk operable prostate cancer will be treated with TAK-700 (plus LHRH agonist) for 24 weeks prior to planned prostatectomy.
详细描述
Study Objectives:
To investigate if neoadjuvant TAK-700 with LHRH agonists and prostatectomy is associated with a delay in progression free survival compared to prostatectomy alone
To evaluate response (CR and PR) after at least 12 and 24 weeks of treatment with the study drugs Collection of Plasma, tissue and functional imaging with MRI To evaluate (molecular) expression of AR regulated genes and tumour immunohistochemistry. Molecular and protein expression will be correlated with intracellular androgen levels and pathologic response to ADT
136 patients will be randomised to this study. 68 patients will receive neoadjuvant therapy with TAK-700 and Leuprorelin Acetate followed by surgery and 68 patients will receive surgery alone.
This trial aims to recruit 136 patients with clinically localised prostate cancer. Patients will be stratified according to National Comprehensive Cancer Network (NCCN) risk stratification criteria and type of planned surgery. Definitions of risk categories can be found in the inclusion and exclusion criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent
- •No previous treatment for prostate cancer (including surgery, any hormone therapy, radiotherapy, cryotherapy).
- •Age ≥ 18 years and male
- •Histologically or cytologically confirmed adenocarcinoma of the prostate with Gleason score. A prostate biopsy within 6 months from screening is allowed for entry requirements.
- •Intermediate or high risk prostate cancer according to National Comprehensive Cancer Network (NCCN) risk stratification criteria
- •Intermediate: PSA >10 & <20 or a Gleason score 7 or clinical stage up to and including T2c disease
- •High risk: PSA>20 or Gleason 8-10 or clinical stage >T2c
- •Serum testosterone > 200 ng/dL
- •Prostatectomy is the planned treatment option.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •Adequate organ function, defined as follows:
- •Hemoglobin >10.0g/dL
- •Absolute neutrophil count > 1.5 x 10.9/L
- •Platelet count >100 x 10.9/L
- •AST and /or ALT <2.5 x ULN
- •Total Bilirubin <1.5 x ULN
排除标准
- •Serious co-existent medical conditions such as chronic active autoimmune disease, (within the last 6 months) or infection (such as hepatitis).
- •Uncontrolled hypertension within the screening period (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg). Patients with a history of hypertension are allowed to enrol provided blood pressure is controlled by anti-hypertensive therapy.
- •Patients taking regular oral steroids for any reason.
- •Previously treated prostate cancer (including radiotherapy, hormone therapy or surgery).
- •History of pituitary or adrenal dysfunction
- •Other active malignancy over the last 5 years that has required systemic therapy excluding:
- •Adjuvant therapy in the curative setting
- •Non-melanoma skin cancer
- •Superficial transitional cell carcinoma (CIS-T1).
- •History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
- •Current enrolment in an investigational drug or device study or participation in such a study within 30 days of Day 1
- •Not willing to comply with the procedural requirements of this protocol, including repeat prostate biopsies
- •Patients who have partners of childbearing potential who are not willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 16 weeks after last study drug administration.
- •Uncontrolled diabetes mellitus, in the opinion of the treating physician
- •Known hypersensitivity to compounds related to TAK-700 or to TAK-700 excipients.
- •Hypersensitivity to any of the ingredients or to synthetic Gn-RH or Gn-RH derivatives.
- •Screening calculated ejection fraction of <50% by echocardiogram.
- •History of myocardial infarction, unstable symptomatic ischemic heart disease, ongoing arrhythmias of Grade > 2 (NCI CTCAE, version 4.02), thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (e.g., pericardial effusion restrictive cardiomyopathy) within 6 months prior to first dose of study drug. Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed.
- •New York Heart Association Class III or IV heart failure
- •ECG abnormalities of Q-wave infarction, unless identified 6 or more months prior to screening
- •QTc interval > 460 msec on ECG
研究组 & 干预措施
Prostatectomy
Prostatectomy only-Within 28 days of randomisation
干预措施: prostatectomy (Procedure)
TAK-700 + LHRH agonist + Prostatectomy
Neoadjuvant TAK-700 for 6 months with LHRH agonists prior to prostatectomy
干预措施: TAK-700 and LHRH agonist (Drug)
结局指标
主要结局
3 year biochemical progression free survival (PSA)
时间窗: 3 years
Post-operative serum PSA of greater or equal to 0.2 ng/dl on 2 separate occasions as defined by the AUA.
次要结局
未报告次要终点
研究者
Centre of Experimental Medicine
Professor Thomas Powles
Queen Mary University of London